购物车
- 全部删除
- 您的购物车当前为空
KRASG12C IN-16 (Compound SK-17) 是一种选择性、共价、口服活性的KRASG12C抑制剂。它能够诱导细胞凋亡 (Apoptosis),并有效阻止MAPK和PI3K/mTOR信号通路的激活,展现出对胰腺癌的抗肿瘤活性。
KRASG12C IN-16 (Compound SK-17) 是一种选择性、共价、口服活性的KRASG12C抑制剂。它能够诱导细胞凋亡 (Apoptosis),并有效阻止MAPK和PI3K/mTOR信号通路的激活,展现出对胰腺癌的抗肿瘤活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 待询 | 期货 | |
50 mg | 待询 | 期货 |
产品描述 | KRASG12C IN-16 (Compound SK-17) is a selective, covalent, and orally active KRASG12C inhibitor. It can induce apoptosis and effectively prevent the activation of the MAPK and PI3K/mTOR signaling pathways. Additionally, KRASG12C IN-16 exhibits antitumor activity against pancreatic cancer. |
分子量 | 551.08 |
分子式 | C28H35ClN8O2 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容